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Abstract
Gliomas are the most common tumors in the central nervous system, the average survival time of patients with
glioblastoma multiforme being about 1 year from diagnosis, in spite of harsh therapy. Aiming to study the
transcriptional profiles displayed by glioma cells undergoing cisplatin treatment, gene expression analysis was per-
formed by the cDNA microarray method. Cell survival and apoptosis induction following treatment were also evalu-
ated. Drug concentrations of 12.5 to 300 M caused a pronounced reduction in cell survival rates five days after
treatment, whereas concentrations higher than 25 M were effective in reducing the survival rates to ~1%. However,
the maximum apoptosis frequency was 20.4% for 25 M cisplatin in cells analyzed at 72 h, indicating that apoptosis
is not the only kind of cell death induced by cisplatin. An analysis of gene expression revealed 67 significantly
(FDR < 0.05) modulated genes: 29 of which down- and 38 up-regulated. These genes belong to several classes (me-
tabolism, protein localization, cell proliferation, apoptosis, adhesion, stress response, cell cycle and DNA repair) that
may represent several affected cell processes under the influence of cisplatin treatment. The expression pattern of
three genes (RHOA, LIMK2 and TIMP2) was confirmed by the real time PCR method.
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Introduction
Malignant gliomas are the most common primary ma-
lignancies in the brain, comprising more than 60% of pri-
mary brain tumors (Huang et al., 2002; Iwadate et al., 1996;
Kunwar et al., 2001). In an adult population, this type of tu-
mor accounts for about 1% of all cancers, with more than
2% of deaths being attributed to malignant gliomas (Wong
et al., 2007). The average survival time of patients with the
most malignant type, glioblastoma multiforme, is about 1
year after diagnosis, irrespective of the aggressive combi-
nation of surgery, radiotherapy and chemotherapy. Progno-
sis, in the case of malignant astrocytic gliomas, is dismal,
due to their ability to diffusely infiltrate into the normal
brain parenchyma. In cell cultures, malignant glioma cells
proved to be very resistant to apoptosis induced by various
anticancer agents (Bogler and Weller, 2002; Iwamaru et al.,
2007; Lefranc et al., 2005). In spite of advances in anti-
cancer therapies, the prognosis for glioma patients is still
very discouraging (Ohgaki, 2005).
Cisplatin is a DNA-damaging agent used in first-line
chemotherapy against epithelial malignancies of the lungs,
ovaries, bladder, testis, head, neck, esophagus, gut, colon
and pancreas, as also in second- and third-line treatment
against a number of metastatic malignancies, including
breast and prostate cancer, melanomas, malignant gliomas
and others (Boulikas and Vougiouka, 2004). Cisplatin
forms primarily 1,2-intrastrand crosslinks between adja-
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cent purines in DNA and also introduces DNA 1,3-intras-
trand crosslinks and, to a lesser extent, interstrand
crosslinks. The mechanisms of cisplatin-induced cytotoxi-
city are not completely understood yet. However, it has
been reported that the antitumoral activity of cisplatin is
probably due to the formation of DNA adducts that block
DNA replication and transcription, thereby triggering cel-
lular responses, including apoptosis (Brabec and Kaspar-
kova, 2005; Torigoe et al., 2005; Zhang et al., 2006).
The development of cDNA microarrays technology
has facilitated the analysis of gene expression profiles that
can generate a large body of information on genes and path-
ways related to the response to several antitumoral drugs
(Li et al., 2007).
In order to investigate how glioma cells respond to
antitumoral cisplatin, we measured cell survival and apop-
tosis induction, in addition to analysis of gene expression
displayed by cisplatin-treated compared with untreated
U343 cells, by using the cDNA microarray technique. This
approach was propitious for registering significantly modu-
lated genes that play important roles in the innumerous sig-
naling pathways involved in cisplatin-treated glioma cells.
While providing a general characterization of cisplatin
cytotoxicity in U343 cells, we showed that at conditions of
moderate to high drug cytotoxicity (25 M cisplatin), capa-
ble of inducing a significant reduction in survival rates after
5 days of treatment, transcriptional changes involved the
modulation of several genes belonging to diverse func-
tional categories. The main biological processes associated
with these modulated genes were metabolism, cell prolifer-
ation, apoptosis, cell adhesion, stress response, cell cycle
control and DNA repair.
Material and Methods
Cell culture conditions and reagents
Human glioma cell line U343 was kindly provided by
Dr. James T. Rutka (The Arthur and Sonia Labatt Brain Tu-
mour Research Center, Canada). MRC-5 (SV-40 trans-
formed fibroblast cell line) was provided by Dr. Carlos F.
M. Menck (ICB-USP, São Paulo, Brazil). Cells were rou-
tinely grown in Dulbecco’s modified Eagle’s medium
(DMEM) + F10 (1:1) (Sigma Aldrich, St. Louis, MO,
USA), supplemented with 15% fetal bovine serum (Cul-
tilab, Campinas, SP, Brazil), ciprofloxacin and kanamicin
in 25 cm2 culture flasks (Corning, NY, USA). The cell cul-
tures were kept at 37 °C in a humidified atmosphere of 5%
CO2. Cisplatin (Sigma Aldrich, St. Louis, MO, USA) was
dissolved in sterile water just before use.
Cell survival
Cells were treated with 12.5; 25; 50; 75; 150 and
300 M cisplatin and harvested at 24 h and 5 days later.
Cell survival after cisplatin treatment was measured by us-
ing the Cell Proliferation Kit II (Roche) containing the
tetrazolium salt XTT. Surviving cells with active mito-
chondria are capable of cleaving the XTT substrate into an
orange formazan dye. After 1 h incubation, the amount of
formazan dye can be measured by spectrophotometry
(Amersham Biosciences, England, UK) analysis performed
at optical densities (OD) of 492 and 690 nm. Cell survival
was calculated as the percentage of absorbance displayed
by cisplatin treated cells compared to untreated cells. Each
experiment was repeated at least three times.
Apoptosis detection
Cisplatin-induced apoptosis was determined using a
mixture of propidium iodide (5 g/mL), fluorescein dia-
cetate (15 g/mL) and Hoechst 33342 (2 g/mL) (all from
Sigma Aldrich, St. Louis, MO, USA). Cells treated with
several concentrations of cisplatin (12.5; 25 and 50 M)
were harvested at different times (24, 48 and 72 h) after
treatment. Floating and adherent cells were collected and
stained. 500 cells per treatment were examined through a
fluorescence microscope (Axiophot, Zeiss) to score apop-
totic cells. At least three independent experiments were car-
ried out.
RNA extraction and gene expression
Experiments for gene expression analysis were car-
ried out on U343 cells treated with 25 M cisplatin for 48 h.
A total of four independent experiments were made, and
RNA extraction was performed at 48 h following cisplatin
treatment. Total RNA was isolated from cultured cells us-
ing the Trizol reagent according to manufacturer’s instruc-
tions. The integrity of RNA samples was evaluated by
denaturing agarose gel electrophoresis under standard con-
ditions.
cDNA microarrays
For gene expression analysis, 936 cDNA clones from
the IMAGE consortium were used to construct the micro-
array on nylon membrane. These clones, kindly provided
by Dr Catherine Nguyen (INSERM, Marseille, France),
were amplified on 96-well plates by polymerase chain reac-
tion (PCR). The PCR products were purified and spotted in
duplicate onto Hybond N+ membranes (Amersham Phar-
macia Biotech, Buckinghamshire, UK), using the Genera-
tion III Microarray Spotter device (Amersham Pharmacia
Biotech, Buckinghamshire, UK).
cDNA probe labeling and hybridization
Hybridization was carried out with a 33P-labeled oli-
gonucleotide, using the T4 kinase labeling kit (Invitrogen,
Carlsbad, CA). Membranes were pre-hybridized in a hy-
bridization mix (5x SSC, 5x Denhardt’s solution, 0.5%
SDS and 100 g/mL of salmon sperm DNA) at 42 °C for
24 h, followed by hybridization with the vector probe 1S at
42 °C for 24 h. Membranes were washed with 2x SSC,
0.1% SDS solution for 10 min at room temperature, and ex-
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posed to radiation-sensitive imaging plates for 24 h. Hy-
bridization signals were detected in a phosphor image
device (Cyclone, Packard Instruments, USA).
The complex probe was prepared with 10 g of total
RNA and 8 g of oligo(dT)25. The reaction mixture was in-
cubated for 8 min at 70 °C, and then cooled to 42 °C. This
process improves long polyA tail saturation. Reverse tran-
scription was performed in a reaction mixture containing
1 L of RNasin (Promega, 40U/ul), 6 L of buffer 5x, 2 L
of DTT 0.1 M, 0.6 L of dATP 20 mM, 0.6 L of dTTP
20 mM, 0.6 L of dGTP 20 mM, 0.6 L of dCTP 120 M,
3 L of  33P-dCTP, 1 L of reverse transcriptase
(SUPERSCRIPT RNase H free RT, Invitrogen, 200 U/L),
and 2.8 L of sterile water. After 1 h at 42 °C, 1 L of re-
verse transcriptase was added and the mix was incubated
for 1 h at 42 °C. Subsequently, 1 L of SDS 10%, 1 L of
EDTA 0.5 M and 3 L of NaOH 3 M were added to the
mixture in order to degrade mRNA and rRNA templates.
The reaction mixture was incubated for 30 min at 68 °C and
then for 15 min at room temperature. Finally, 10 L of Tris
1 M, 3 L of HCl 2N were added to neutralize the reaction.
The volume was completed to 100 L, and the probe puri-
fied on a Sephadex G-50 column.
Membranes were placed into hybridization flasks,
and hybridization with the complex probe was performed at
65 °C for 48 h, followed by washes with 0.1x SSC, 0.1%
SDS at 68 °C for 3 h, and exposure to radiation-sensitive
imaging plates for 48 h. Images were captured in a phos-
phor image device (Cyclone, Packard Instruments, USA).
Thereafter, numerical values obtained for hybridization
signals were quantified by using the BZScan software
(Rougemont and Hingamp, 2003).
Analysis of microarray data
Data obtained by using the BZScan software were
normalized through the following steps: background sub-
traction; normalization of the amount of spotted cDNA by
oligo-vector labeling values and correlation-based filtering
of array elements, which indicated unreliable elements with
low correlation. A global normalization procedure was per-
formed, which consisted of dividing all the individual spot
values obtained in one experiment by the median value cal-
culated for the whole experiment (Quackenbush, 2002).
The normalized data were analyzed by MEV software. Sta-
tistical analysis by t-test and SAM (Significance Analysis
of Microarrays) method (Tusher et al., 2001) were per-
formed in order to select significantly modulated genes at a
FDR (False Discovery Rate) < 0.05. In order to search for
gene functions, the data were submitted to S.O.U.R.C.E.
(Stanford Online Universal Resource for Clones and
ESTs), NCBI and DAVID-NIH (Dennis et al., 2003). For
three genes, the transcriptional profiles were confirmed by
the real-time PCR method.
Real time PCR method
A quantitative real time PCR (qPCR) method was
used to confirm gene expression profiles for three genes,
TIMP2, RHOA and LIMK2. RNA samples used in cDNA
microarrays were submitted to decontamination of DNA
traces by the treatment with the Deoxyribonuclease I, Am-
plification Grade kit (Invitrogen), according to manufac-
turer’s instructions. The reverse transcription step was
carried out with the Superscript III Reverse Transcriptase
kit (Invitrogen) according to manufacturer’s instructions,
using DNAse-treated RNA samples as a template. The
integrity of the obtained cDNA samples was tested by am-
plification of the endogenous actin- (ACTB) gene, and vi-
sualization by agarose gel electrophoresis. qPCR was
carried out using SYBR green master mix (Applied Bio-
systems) and the Ct method (Livak and Schmittgen,
2001). Each reaction had a total volume of 15 L, contain-
ing 5.4 L of water, 7.5 L of SYBR Green, 0.75 L
(10 M stock) of each forward and reverse primers (manu-
factured at Integrated DNA Technologies, USA) and
0.6 L of cDNA obtained from RT-PCR reactions, for each
sample. The reactions were mounted in 96 wells poly-
propylene plates covered with microplate adhesives. The
reactions were carried out in an Applied Biosystems 7500
Real-Time PCR System (Applied Biosystems, UK) using
the primer sets TIMP2: forward 5’ - TTC CCT CCC TCA
AAG ACT GA - 3’, reverse 5’ - CGT CTG GCT AAT TGC
ATC CT - 3’; RHOA: forward 5’- GAG TTG GCT TTG
TGG GAC AC - 3’, reverse 5’ - ACT ATC AGG GCT GTC
GAT GG - 3’; LIMK2: forward 5’ - TGC ACA TCA GTC
CCA ACA AT - 3’, reverse 5’ - CGT CTG GCT AAT TGC
ATC CT - 3’; ACTB: forward 5’- TTG CCG ACA GGA
TGC AGA AGG A - 3’, reverse 5’- AGG TGG ACA GCG
AGG CCA GGA T- 3’, with an annealing temperature near
60 °C and an amplicon of 100-150 bp. PCR conditions
were: 50 °C for 2 min, 10 min at 95 °C, followed by 40 cy-
cles at 95 °C for 15 s, and at 60 °C for 60 s. Dissociation
curves were set up as follows: 95 °C for 15 s, 60 °C for 20 s
and 95 °C for 15 s.
Statistical analysis
Statistical analyses for survival and apoptosis induc-
tion assays were performed by using the Student’s t test,
and a value of p  0.05 was considered as significant.
Results
The cytotoxic effect of cisplatin was analyzed in
U343 and MRC-5 cells treated with different drug concen-
trations (12.5; 25; 50; 75; 150 and 300 M). After 24 h of
treatment (Figure 1A), cisplatin induced a 20 to 80% reduc-
tion in U343 cell survival, with a marked reduction in sur-
vival rates to less than 1% after 5 days of drug treatment
(Figure 1B). MRC-5 cells also showed a reduction in sur-
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vival fractions after 24 h of cisplatin treatment similarly as
U343 cells (Figure 1A), although after 5 days (Figure 1B),
this was only slight when compared to U343 cells.
Cisplatin-induced apoptosis occurred in U343 cells
after treatment with 12.5, 25 and 50 M for 24, 48 and 72 h
(Figure 2). Analysis of cell morphology revealed apoptotic
cells even after 24 h of treatment (3%), with higher frequen-
cies after 48 (8%) and 72 h (20.4%) for 25 M cisplatin.
The apoptosis frequency displayed by MRC-5 cells after
cisplatin treatment (Figure 3) was very low (4%). Thus, on
the basis of these results, the U343 glioma cell line proved
to be more sensitive to cisplatin than the normal fibroblast
cell line (MRC-5) under similar conditions. On the con-
trary, the T98G glioma cell line was very resistant to cis-
platin treatment at increasing concentrations (data not
shown).
Alterations in gene expression were evaluated in
U343 cells treated with 25 M cisplatin, and RNA extrac-
tion was performed after 48 h. Statistical analysis was car-
ried out by the SAM method, which indicated a total of 67
differentially expressed genes: 29 down-regulated and 38
up-regulated genes at a FDR < 0.05 (Table 1). Regarding to
biological functions attributed to the set of significant
genes, the most frequent categories (represented by a vari-
able number of genes) were related to metabolism, ubi-
quitin-proteasome, cell proliferation, adhesion, apoptosis,
cell cycle and DNA repair.
By applying the real time PCR method, we confirmed
the down-regulation of RHOA, LIMK2 and TIMP2 genes,
by using the same remaining RNA samples as those em-
ployed in the microarray experiments. The results indicated
similar gene expression patterns obtained by both methods
(Figure 4). These genes were selected based on their func-
tions associated with glioma cells. There were certain vari-
ations regarding the magnitude of relative expression,
although gene expression modulation occurred in the same
direction.
Discussion
It is well known that cisplatin cytotoxicity is attrib-
uted to the formation of various DNA adducts that trigger
cellular responses culminating in cell death (Zhang et al.,
2006). Studies on the quantitative and qualitative modula-
tion of gene expression profiles under conditions of drug
treatment is an interesting approach to characterize the
162 Carminati et al.
Figure 1 - Cell survival. U343 and MRC-5 cell lines were treated with increasing concentrations of cisplatin (12.5; 25; 50; 75; 150 and 300 M). The cells
were harvested 24 h (A) and 5 days (B) after treatment (mean  SD). Cell survival was measured by XTT assay.
Figure 2 - Frequency of apoptotic cells in U343 cell cultures treated with
different concentrations of cisplatin (12.5; 25 and 50 M). The results
were obtained 24, 48 and 72 h after treatment. 500 cells were analyzed for
each experiment (mean  SD).
Figure 3 - Frequency of apoptotic cells in MRC-5 cell cultures treated
with different concentrations of cisplatin (12.5; 25 and 50 M). The results
were obtained 24, 48 and 72 h after treatment. 500 cells were analyzed for
each experiment (mean  SD).
Glioma cell responses to cisplatin 163
Table 1 - Genes differentially expressed in the U343 glioma cell line after cisplatin treatment (25 M for 48 h) selected through SAM analysis
(FDR < 0.05).
Gene symbol Unigene ID Description Fold-change Function
LIMK2 Hs.474596 LIM domain kinase 2 -3.87 Metabolism
BCLXL Hs.516966 BCL2-like 1 -2.48 Apoptosis
TIMP2 Hs.633514 Tissue inhibitor of metalloproteinase 2 -3.96 Cell Proliferation
VDP Hs.292689 USO1 homolog, vesicle docking protein (yeast) -3.53 Intracellular Transport
COG4 Hs.208680 Component of oligomeric golgi complex 4 -3.03 Protein Transport
RHOA Hs.247077 Ras homolog gene family, member A -2.95 Cell Proliferation
OPCML Hs.4817 Opioid binding protein/cell adhesion molecule-like -2.91 Adhesion
RQCD1 Hs.148767 RCD1 required for cell differentiation1 homolog (S. pombe) -2.70 Transcription
ING1 Hs.46700 Inhibitor of growth family, member 1 -2.48 Cell Proliferation
FLRT1 Hs.584876 Fibronectin leucine rich transmembrane protein 1 -2.48 Adhesion
ING1 Hs.46700 Inhibitor of growth family, member 1 -2.48 Cell Cycle
COX4I1 Hs.433419 Cytochrome c oxidase subunit IV isoform 1 -2.11 Metabolism
GTF3C1 Hs.371718 General transcription factor IIIC, polypeptide 1, alpha
220kDa
-1.84 Transcription
TBCD Hs.464391 Tubulin folding cofactor D -1.79 Metabolism
CALU Hs.7753 calumenin precursor -1.69 Other Functions
MOCS2 Hs.163645 Molybdenum cofactor synthesis 2 -1.67 Metabolism
P4HB Hs.464336 Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline
4-hydroxylase), beta polypeptide
-1.65 Metabolism
PASK Hs.397891 PAS domain containing serine/threonine kinase -1.59 Signal transduction
FZD4 Hs.591968 Frizzled homolog 4 (Drosophila) -1.50 Other Functions
SPOP Hs.463382 Speckle-type POZ protein -1.37 RNA processing
CXCL10 Hs.632586 Chemokine (C-X-C motif) ligand 10 -1.24 Cell Signaling
NFKBIE Hs.458276 Nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, epsilon
-1.13 Protein Localization
AP3S2 Hs.632161 Adaptor-related protein complex 3, sigma 2 subunit -1.02 Protein Localization
DLX6 Hs.249196 Distal-less homeobox 6 -1.01 Regulation of Transcrip-
tion
DYRK3 Hs.164267 Dual-specificity tyrosine-(Y)-phosphorylation regulated
kinase 3
-0.90 Metabolism
TBRG1 Hs.436410 Transforming growth factor beta regulator 1 -0.72 Cell Cycle
AKAP7 Hs.486483 A kinase (PRKA) anchor protein 7 -0.71 RNA Metabolism
GNB1 Hs.430425 Guanine nucleotide binding protein (G protein), beta
polypeptide 1
-0.69 Cell Proliferation
FUT8 Hs.654961 Fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 0.10 Metabolism
PAPOLA Hs.253726 Poly(A) polymerase alpha 0.11 Transcription
KCNV1 Hs.13285 Potassium channel, subfamily V, member 1 0.11 Ion Transport
CRADD Hs.591016 CASP2 and RIPK1 domain containing adaptor with death
domain
0.13 Apoptosis
ARPP21 Hs.475902 cyclic AMP-regulated phosphoprotein, 21 kD 0.13 Other Functions
SRPK2 Hs.285197 SFRS protein kinase 2 0.14 Cell Differentiation
KCNIP4 Hs.655705 Kv channel interacting protein 4 0.17 Ion Transport
BTF3 Hs.591768 Basic transcription factor 3 0.28 Transcription
TNFRSF1OB Hs.521456 Tumor necrosis factor receptor superfamily, member 10b 0.47 Apoptosis
RGS4 Hs.386726 Regulator of G-protein signaling 4 0.47 Signal Transduction
CPLX2 Hs.193235 Complexin 2 0.64 Other Functions
EIF4G1 Hs.433750 Eukaryotic translation initiation factor 4 gamma, 1 1.07 RNA Metabolism
SEPT2 Hs.335057 Septin 2 1.33 Cell Cycle
IL10 Hs.193717 Interleukin 10 1,41 Immune Response
SFRS11 Hs.479693 Splicing factor, arginine/serine-rich 11 1.44 RNA Splicing
mechanisms by which chemotherapeutic agents act on can-
cer cells. Although cisplatin has been used for a long time,
the molecular mechanisms of cell responses associated to
its cytotoxic activity are poorly clarified. In the present
work, we first studied the potential of cisplatin to induce
cell death in the glioma U343 cell line. When compared to
the SV40 transformed fibroblast cell line (MRC-5), U343
cells proved to be the more sensitive to cisplatin.
Survival experiments carried out with increasing drug
concentrations confirmed the high potential of cisplatin to
induce cytotoxic effects, as well as apoptosis, in U343 cells.
Furthermore, a strong residual cytotoxic effect could still
be observed several days following drug treatment. Sur-
vival analysis performed after 5 days demonstrated a sig-
nificant reduction in the survival rates following drug
treatment (12.5 to 300 M), and a pronounced effect was
observed at concentrations higher than 25 M. The analysis
of apoptosis showed that 25 M cisplatin induced 20.4% of
apoptotic cells following 72 h, indicating that some consid-
erable proportion of cells died by apoptosis. However,
damaged cells can also be effectively eliminated by other
processes, such as necrosis, mitotic catastrophe, autophagy,
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Figure 4 - Gene expression levels determined by the cDNA microarray
and real time PCR methods for RHOA, LIMK and TIMP2. The same RNA
samples were used in both methods. The ct-values represent the log ra-
tio (base 2).
Table 1 (cont.)
Gene symbol Unigene ID Description Fold-change Function
APIP Hs.447794 APAF1 interacting protein 1.45 Apoptosis
ADAMTS1 Hs.643357 ADAM metallopeptidase with thrombospondin type 1 mo-
tif, 1
1.61 Cell Proliferation
TAF4 Hs.18857 TAF4 RNA polymerase II, TATA box binding protein
(TBP)-associated factor, 135kDa
1.76 Regulation of Biological
Process
ULK2 Hs.168762 Unc-51-like kinase 2 (C. elegans) 1.79 Metabolism
STAM Hs.441498 Signal transducing adaptor molecule (SH3 domain and
ITAM motif) 1
1.80 Signal Transduction
GPR108 Hs.167641 G protein-coupled receptor 108 1.80 Other Functions
MSX1 Hs.424414 Msh homeobox 1 1.97 Other Functions
RAB37 Hs.592097 RAB37, member RAS oncogene family 2.23 Signal Transduction
NFRKB Hs.530539 Nuclear factor related to kappaB binding protein 2.52 Response to Stress
USP38 Hs.480848 Ubiquitin specific peptidase 38 2.63 Ubiquitin-Proteasome
PCDH17 Hs.106511 Protocadherin 17 2.79 Adhesion
MECP2 Hs.200716 Methyl CpG binding protein 2 (Rett syndrome) 2.82 Transcription
TIAM1 Hs.517228 T-cell lymphoma invasion and metastasis 1 2.92 Adhesion
TUSC4 Hs.437083 Tumor suppressor candidate 4 3.06 Cell Cycle
POLR2K Hs.351475 Polymerase (RNA) II (DNA directed) polypeptide
K, 7.0kDa
3.07 Transcription
PSMA1 Hs.102798 Proteasome (prosome, macropain) subunit, alpha type, 1 3.20 Ubiquitin-Proteasome
SEMA6A Hs.156967 Sema domain, transmembrane domain (TM), and cytoplas-
mic domain, (semaphorin) 6A
3.35 Apoptosis
CDH13 Hs.654386 Cadherin 13, H-cadherin (heart) 3.38 Adhesion
NEK8 Hs.448468 NIMA (never in mitosis gene a)- related kinase 8 3.41 Other Functions
RAD51C Hs.412587 RAD51 homolog C (S. cerevisiae) 3.73 DNA Repair
P2RX4 Hs.321709 Purinergic receptor P2X, ligand-gated ion channel, 4 3.80 Apoptosis
TNFAIP1 Hs.76090 Tumor necrosis factor, alpha-induced protein 1 (endothelial) 4.01 Immune Response
INSM1 Hs.89584 Insulinoma-associated 1 4.74 Cell differentiation
GTF3C4 Hs.656646 General transcription factor IIIC, polypeptide 4, 90kDa 5.01 Transcription
as well as premature senescence, which irreversibly arrests
cell division (Brown and Attardi, 2005).
We also tested temozolomide against a panel of glio-
ma cell lines, viz., U343, U87, U251, U138 and T98G, in
the laboratory, and only T98G cells were found to be sensi-
tive to various concentrations of temozolomide (data not
shown). According to other authors, cisplatin decreased the
viability of A172 glioma cells in a time- and dose-depen-
dent manner. Furthermore, cisplatin induced cytotoxicity in
A172 cells showed characteristics related to apoptosis
(Park et al., 2006). Apoptosis is a common response of cells
to platinum compounds (Sorenson et al., 1990), and ac-
cordingly, in the present study we observed apoptosis as the
primary effect of cisplatin on glioma cells.
Evaluation of gene expression can provide informa-
tion on regulatory mechanisms, biochemical pathways and
potential targets for clinical intervention and therapies in a
variety of diseases (Zhang et al., 2006). The expression
profiles of drug-treated cells can be readily compared with
untreated control cells to reveal sets of genes that have un-
dergone alterations at the transcriptional level in response
to drug treatment (Duale et al., 2007). In the present study,
the findings concerning gene expression profiles disclosed
67 significantly modulated genes in U343 cells treated with
25 M cisplatin for 48 h. The experimental conditions of
drug treatment were chosen on the basis of results from sur-
vival and apoptosis experiments. The statistical analysis
carried out by SAM was applied to identify those gene sig-
natures whose mRNA levels were significantly and differ-
entially expressed between cisplatin- treated and untreated
U343 cells. The quantitative results of gene expression in-
dicated a set of up- and down-regulated genes, mainly
related to metabolism, ubiquitin-proteasome, cell prolifera-
tion, adhesion, apoptosis, cell cycle control and DNA re-
pair. Among the exclusively modulated genes, only a few
were selected for discussion, and this was mainly due to
their biological relevance. In the case of three genes
(RHOA, LIMK2 and TIMP2), the expression pattern was
confirmed by the real time PCR technique, and was com-
patible with the results obtained by the microarray method.
In the set of genes modulated by cisplatin, the most
frequent category was related to metabolism, represented
by two up-regulated (FUT8 and ULK2) and six down-
regulated genes (COX4I1, DYRK3, TBCD, LIMK2,
MOCS2 and P4HB).
Some of these, such as DYRK3, play a role in cell
growth and development in the glioma cell line (Yamanaka
et al., 2006), whereas LIMK2 is involved in stress fiber and
focal adhesion formation and membrane blebs during the
apoptotic process. The down-regulation of LIMK2, also
demonstrated by the real time PCR method, may affect sev-
eral functions, including apoptosis induction. In fibrosar-
coma, the reduced expression in LIMK2 protein was found
to restrict the metastatic potential (Suyama et al., 2004).
Some modulated genes, such as USP38 and PSMA1, were
related to the proteasome system. The ubiquitin-protea-
some system is responsible for the degradation of both
damaged proteins and regulators of growth and stress re-
sponse. Alterations in this proteolytic system are associated
with various forms of human pathologies (Deng et al.,
2007). Ubiquitin specific proteases (USPs) belong to a
complex family of deubiquitinating enzymes that specifi-
cally cleave ubiquitin conjugates in a great variety of sub-
strates, thereby regulating the production and recycling of
ubiquitin itself, and are critically involved in the control of
cell growth, differentiation, and apoptosis (Ovaa et al.,
2004; Rolen et al., 2006).
U343 cells treated with cisplatin also showed up-
regulated (ADAMTS1 and CDH13), and down-regulated
genes (GNB1, TIMP2, RHOA and ING1) related to cell pro-
liferation. ADAMTS1 negatively regulates tumor growth
and metastasis (Vazquez et al., 1999; Luque et al., 2003;
Choi et al., 2008) , whereas TIMP2 takes part in degrading
ECM (extracellular matrix) and regulating the invasion
process (Lu et al., 2004), considered the root cause of the
high recurrent incidence in glioblastoma (Kong et al.,
2007). TIMPs have also been shown to exert pluripotential
effects on cell growth, apoptosis and differentiation (Baker
et al., 2002; Jiang et al., 2002). Similar to TIMP2, the
RHOA gene was also down-regulated in cisplatin-treated
glioma cells, and the decreased expression levels were also
confirmed through real time PCR analysis. The protein en-
coded by RHOA is involved in cell proliferation/stress re-
sponse, and belongs to the Rho GTPases family which
participates in cell growth, lipid metabolism cytoarchi-
tecture, membrane trafficking, transcriptional regulation
and apoptosis in response to genotoxic agents. They trigger
specific signals that lead to uncontrolled cell growth, en-
hanced angiogenesis, inhibition of apoptosis and genetic
instability, thus resulting in tumor development (Aznar and
Lacal, 2001; Lu et al., 2009). In astrocytomas, RHOA ex-
pression positively correlates with the degree of malig-
nancy (Yan et al., 2006).
One of the most distinct features of gliomas is the in-
vasive growth pattern, which prevents total surgical resec-
tion. Their ability to infiltrate into normal brain
parenchyma is associated to the process of cellular adhe-
sion (Giese et al., 1994). In the present work, we found five
modulated genes under cisplatin treatment, which are clo-
sely related to adhesion. Among these, CDH13, TIAM1 and
PCDH17 were up- and FLRT1 and OPCML down-
regulated, thus indicating that the invasion capacity of
glioma cells can be altered by cisplatin treatment.
OPCML is significantly down-regulated in brain tu-
mors, including gliomas (Reed et al., 2007). This is a
stress-responsive and TP53-regulated gene, capable of act-
ing as a broad tumor suppressor for multiple tumor types
(Cui et al., 2008). The protein encoded by this gene is an
opioid-binding cell adhesion molecule, which is often
found methylated in ovarian cancers (Sellar et al., 2003).
Glioma cell responses to cisplatin 165
Tumor cell invasion involves complex interactions be-
tween normal and malignant cells. It is well established that
this dynamic process requires the concerted effects of vari-
ous molecules including proteolytic enzymes, growth fac-
tors, adhesion molecules and extracellular matrix
molecules (Cui et al., 2008).
Cell response to induced DNA damage is a highly
complex event that is orchestrated by a multitude of pro-
teins and signaling pathways operating together in a cell
context to activate mechanisms of DNA repair, cell cycle
arrest and apoptosis, all depending on the extent of the
DNA damage. In the present work, we analyzed gene ex-
pression profiles under conditions of apoptosis induction
by cisplatin in the U343 cell line. Several modulated genes
were related to apoptotic cell death (TNFRSF10B, BCL-XL,
APIP, SEMA6A, CRADD and P2RX4). These findings sug-
gest that the altered expression pattern of apoptosis related
genes caused by cisplatin may be involved in chemosen-
sitivity, as observed in survival assaying and in the fre-
quency of induced apoptosis. Duale et al. (2007) found
several apoptosis related genes in testicular germ cell tu-
mors after cisplatin exposure (including BCL-2 family
genes), suggesting the sensitivity of these cell lines to
chemotherapeutic agents.
Some other cisplatin-modulated genes were related to
cell cycle control (TBRG1, SEPT2, ING1 and TUSC4) and
DNA repair (RAD51C). Septins are involved in several pro-
cesses, including membrane dynamics, vesicle trafficking,
apoptosis, infection and cytoskeletal remodeling (Hall et
al., 2005). SEPT2 is a cell cycle-regulated protein, essential
for cytokinesis in human astrocytoma cells (Kim et al.,
2004). Kremer et al. (2007) demonstrated a link between
septins, the actin cytoskeleton and DNA damage check-
point response.
ING proteins play a significant role in several impor-
tant cellular processes, such as growth regulation, senes-
cence, apoptosis, DNA repair and cell migration (Ythier et
al., 2008; Shah et al., 2009)). TP53 target genes such as
p21WAF1 and BAX, have previously been identified as
downstream targets of p33ING1 and p32ING2 (isoforms of
the ING family) (Feng et al., 2006). LN229 glioblastoma
cells differentially up-regulated p47ING1a in response to
cisplatin, this possibly representing a protective response
against drug-induced DNA damage (Tallen et al., 2008).
The HRR (Homologous Recombination Repair)
pathway is critically important in the repair of DNA dam-
age induced by crosslink agents, such as cisplatin (Golding
et al., 2004; Jayathilaka et al., 2008). However, only the
RAD51C gene was induced in cisplatin-treated glioma
cells, probably due to the high level of drug cytotoxicity at
the conditions tested. RAD51 plays a role in the strand inva-
sion and exchange between a free DNA-end proximal to the
damaged site and a homologous double stranded DNA
(Kuznetsov et al., 2009).
In U373 glioblastoma cells undergoing cisplatin
treatment, several genes were modulated, including those
encoding proteins involved in transcriptional regulation,
stress response, signal transduction, metabolism, cell struc-
ture and adhesion, apoptosis and survival, inflammation
and immune responses, and other processes (Ma et al.,
2006). Li et al. (2007) encountered altered expression in
several genes involved in DNA repair, apoptosis, cell cycle
control and metabolism in ovarian cancer cells that had
been exposed to cisplatin for several hours, whereas Bassi
et al. (2008) also came upon genes connected with DNA re-
pair modulated in response to ionizing radiation in U343
glioma cells.
In conclusion, cisplatin-treated U343 cells showed
transcriptional changes that reflect several biological pro-
cesses that were affected in consequence of drug treatment.
These processes are related to the extensive DNA damage
caused by cisplatin treatment, visualized through the
amount of induced cell death. These findings highlight the
complexity of cellular responses and the signaling path-
ways ultimately leading to cell death in glioma cells.
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